1. Home
  2. TRUP vs AUPH Comparison

TRUP vs AUPH Comparison

Compare TRUP & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trupanion Inc.

TRUP

Trupanion Inc.

HOLD

Current Price

$28.90

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$14.39

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRUP
AUPH
Founded
2000
1993
Country
US
US
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
TRUP
AUPH
Price
$28.90
$14.39
Analyst Decision
Buy
Buy
Analyst Count
4
4
Target Price
$45.50
$17.25
AVG Volume (30 Days)
530.0K
715.2K
Earning Date
05-15-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
295.65
N/A
EPS
0.45
0.55
Revenue
$1,439,305,000.00
$235,133,000.00
Revenue This Year
$12.42
$21.76
Revenue Next Year
$9.39
$16.45
P/E Ratio
$64.22
$25.97
Revenue Growth
11.95
N/A
52 Week Low
$27.30
$6.83
52 Week High
$57.35
$16.54

Technical Indicators

Market Signals
Indicator
TRUP
AUPH
Relative Strength Index (RSI) 33.08 43.06
Support Level $27.30 $14.18
Resistance Level $34.42 $14.66
Average True Range (ATR) 1.57 0.43
MACD -0.25 0.00
Stochastic Oscillator 24.44 20.74

Price Performance

Historical Comparison
TRUP
AUPH

About TRUP Trupanion Inc.

Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: